# Title

 Food and Drugs. PART 866â€”IMMUNOLOGY AND MICROBIOLOGY DEVICES


# ID

 CFR-2018-title21-vol8.Pt. 866


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|:------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'exceeds', 'within', 'prior to', 'more than', 'greater than', 'equal to', 'maximum', 'less than', 'after', 'minimum', 'minimum of', 'greater', 'at least', 'greater than or equal to', 'exceed']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Duration    | ['30.0 day', '18.0 year', '1.0 year', '60.0 day', '5.0 day', '16.0 hour', '3.0 year', '3.0 minute']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Condition   | ['until', 'unless', 'where', 'if not', 'subject to', 'when', 'provided that', 'if']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Entities    | ['Lyme', 'Tularemia', 'Detection', 'Myoglobin', 'Newborn', 'Certain', 'Quantitation', 'West Nile Virus', 'Properdin', 'Hemopexin', 'Herpes', 'Test', 'Varicella', 'Nucleic', 'Cryptococcus', 'Enriched', 'Automated', 'Assayed', 'Gynecologists', 'Whole', 'Note', 'Coxsackievirus', 'Campylobacter', 'Proteus', 'Schistosoma', 'Brucella', 'Food', 'Sample', 'Haemophilus', 'Reovirus', 'Ceruloplasmin', 'Rhinovirus', 'Molecular', 'Schistosomiasis', 'Antiparietal', 'Salmonellosis', 'German', 'G, M, D', 'Escherichia', 'Anaerobic', 'Blank', 'Ferritin', 'Tumor', 'Dengue', 'Entamoeba', 'Influenza', 'Haptoglobin', 'Cytomegalic', 'Industry', 'Microorganism', 'Treponema', 'Cystic', 'Shigellosis', 'Zinc', 'Chlamydia', 'Rare', 'Tangier', 'XIII, A, S', 'Echovirus', 'Systemic', 'Identical', 'Rubeola', 'Streptococcus', 'Adenovirus', 'Vitro HIV Drug Resistance Genotype Assay', 'Scope', 'Thyroid', 'Clostridium', 'Petri', 'Zoster', 'G, M, D, and E', 'Norovirus', 'Rickettsia', 'Support', 'Shigella', 'Point', 'Isolate', 'Serratia', 'Trypanosoma', 'Mycoplasma', 'Seminal', 'Performance', 'Device', 'Lymphocytic', 'Chagas', 'Salmonella', 'Microbial', 'Chronic', 'U.S', 'Listeria', 'Cohn', 'Histoplasma', 'Parainfluenza', 'Cryptococcosis', 'Poliovirus', 'Klebsiella', 'Measles', 'Accuracy', 'Flavobacteriuim', 'Aspergillus', 'Transport', 'Flavobacterium', 'Ouchterlony', 'Mycobacterium', 'C2, C3, C4, C5, C6, C7, C8, and C9', 'Blastomycosis', 'Rubella', 'Data', 'Aspergillosis', 'Multiplexnucleic', 'Hypersensitivity', 'Breast', 'Endotoxin', 'Total', 'Toxoplasma', 'Erysipelothrix', 'Bordetella', 'Enterovirus RNA', 'Limit', 'Extraction', 'Colostrum', 'Gene', 'Trypanosomiasis', 'Central', 'Fab', 'West', 'Vibrio', 'Culture', 'Radial', 'Microbiological', 'Gonococcal', 'Dd', 'Pathogenic', 'Mumps', 'Malta', 'Crohn', 'Systems', 'Neonatal', 'Ovarian', 'Health', 'Gastric', 'Infectious', 'Sporothrichosis', 'Francisella', 'Trichinella', 'Hemoglobin', 'Rheumatoid', 'Free', 'Echinococcosis', 'African', 'Trichomonas', 'Arizona', 'Equine', 'United States', 'Corynebacterium', 'Respiratory Specimens', 'Coccidioides', 'Sporothrix', 'Wood', 'Fecal', 'Coagulase', 'Neisseria', 'Acute', 'Study', 'Indications', 'Immunoglobulin', 'Prothrombin', 'Radioallergosorbent', 'Antimitochondrial', 'Mass', 'Plasmodium', 'Trichinosis', 'Cytomegalovirus', 'Vitro', 'Rocket', 'Clinical', 'Lactoferrin', 'Rabiesvirus', 'Cholera', 'Multipurpose', 'Tryptase', 'Autosomal', 'Pseudomonas', 'Industry and FDA', 'Oxidase', 'Human', 'Poliomyelitis', 'Carbonic', 'Enterovirus', 'Manual', 'Newborns', 'Transferrin', 'Echinococcus', 'Lactic', 'Genetic', 'Guidance', 'Leptospira', 'Limitations', 'Respiratory', 'Immunoelectrophoresis'] |
| Date        | ['1994-12-01', '1999-02-01', '1993-10-01', '1998-05-01', '2018-07-31', '1997-10-01', '1976-05-28', '2018-09-01']                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |


# Structured Analysis With Context

 


## Constraints

| Constraints              | Context                                                                                                                                    |
|:-------------------------|:-------------------------------------------------------------------------------------------------------------------------------------------|
| after                    | III (Premarket approval) shall not be commercially distributed after the date shown in the regulation classifying the                      |
| before                   | Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a                               |
| before                   | Before FDA requires that a device commercially distributed before the enactment date of the amendments, or a                               |
| after                    | the grace period ending on the 90th day after its promulgation or on the last day of                                                       |
| after                    | the grace period ending on the 90th day after its promulgation or on the last day of                                                       |
| after                    | equivalent, device introduced into commercial distribution on or after May 28, 1976, including a device formerly marketed                  |
| before                   | or declaring completed a PDP for the device before the device is commercially distributed unless it is                                     |
| before                   | an approval under section 515 of the act before  commercial distribution.                                                                  |
| before                   | an approval under section 515 of the act before  being commercially distributed.                                                           |
| before                   | an approval under section 515 of the act before  commercial distribution.                                                                  |
| within                   | or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of                  |
| before                   | must still submit a premarket notification to FDA before introducing or delivering for introduction into interstate commerce               |
| less than                | Test results obtained from short-term ( less than 16 hours) incubation are used to determine the                                           |
| within                   | present, the swab turns a dark purple color within  3 minutes.                                                                             |
| before                   | under section 515 of the act is required before  this device may be commercially distributed.                                              |
| after                    | of microorganisms in specimens during storage of specimens after their collection and during their transport from the                      |
| greater                  | Although Escherichia coli constitutes the  greater part of the microorganisms found in the intestinal                                      |
| before                   | under section 515 of the act is required before  this device may be commercially distributed.                                              |
| minimum                  | device, must meet one of the following two minimum clinical performance criteria: (i) For devices evaluated as                             |
| at least                 | B must be at the point estimate of at least 80 percent with a lower bound of the                                                           |
| greater than or equal to | of the 95 percent confidence interval that is greater than or equal to  70 percent.                                                        |
| at least                 | B must be at the point estimate of at least 95 percent with a lower bound of the                                                           |
| greater than or equal to | of the 95 percent confidence interval that is greater than or equal to  90 percent.                                                        |
| at least                 | A must be at the point estimate of at least 90 percent with a lower bound of the                                                           |
| greater than or equal to | of the 95 percent confidence interval that is greater than or equal to  80 percent.                                                        |
| at least                 | B must be at the point estimate of at least 80 percent with a lower bound of the                                                           |
| greater than or equal to | of the 95 percent confidence interval that is greater than or equal to  70 percent.                                                        |
| at least                 | B must be at the point estimate of at least 95 percent with a lower bound of the                                                           |
| greater than or equal to | of the 95 percent confidence interval that is greater than or equal to  90 percent.                                                        |
| within                   | determined by FDA to be acceptable and appropriate. within                                                                                 |
| within                   | the analytical reactivity testing data can be found. within                                                                                |
| before                   | results in a high mortality rate for infants before  or after birth.                                                                       |
| after                    | a high mortality rate for infants before or after  birth.                                                                                  |
| prior to                 | samples for testing, the effect of freezing samples prior to testing and the effect of multiple freeze/thaw cycles                         |
| at least                 | Within-laboratory precision studies, if appropriate, must include  at least one antibiotic resistant and one antibiotic susceptible strain |
| at least                 | the assay format; however, the panel must include at least one antibiotic resistant and one antibiotic susceptible strain                  |
| after                    | and causes destruction of the intestinal lining (gastroenteritis). after                                                                   |
| after                    | of breast milk begins 1 to 5 days after  childbirth.                                                                                       |
| more than                | (J) Specimen matrix comparison data, if  more than one specimen type or anticoagulant can be tested                                        |
| more than                | be used; (J) Specimen matrix comparison data if more than one specimen type or anticoagulant can be tested                                 |
| less than                | population for Type 1 diabetes mellitus includes subjects less than 18 years old, samples from representative numbers of                   |
| before                   | The cutoff must be selected  before  conducting clinical and analytical studies;                                                           |
| minimum of               | A  minimum of 10 to 15 confirmed positive specimens must be                                                                                |
| more than                | 15 confirmed positive specimens must be obtained from more than 1 site, including relevant annotation, and, at 1                           |
| before                   | include the retest rate, the false positive rate before retest, the final false positive rate, and the                                     |
| minimum of               | rate; (B) Device reproducibility data generated, using a minimum of three sites of which at least two must                                 |
| at least                 | using a minimum of three sites of which at least two must be external sites, with two operators                                            |
| minimum of               | Each site must conduct a  minimum of five runs per operator over five nonconsecutive days                                                  |
| minimum of               | Each site must conduct a  minimum of five runs per operator over five nonconsecutive days                                                  |
| within                   | TREC levels of the specimen must include samples within the measuring range, samples above and below the                                   |
| at least                 | calibrator(s) according to the device instructions for use. at least                                                                       |
| within                   | The range of dilution samples must include samples  within the measuring range, samples above and below the                                |
| minimum of               | The lot-to-lot study must include a  minimum of three lots of each blood spot card that                                                    |
| within                   | a range of TREC levels and include samples within the measuring range, samples above and below the                                         |
| within                   | range of TREC levels and must include samples within the measuring range, samples above and below the                                      |
| more than                | (A) Gene (or list of the genes if  more than one) and variants the test detects (using standardized                                        |
| greater than             | must be measured; accuracy point estimates must be greater than 99 percent (both per reported variant and overall)                         |
| at least                 | allele frequency in ethnically relevant population) must have at least  20 unique heterozygous clinical specimens tested.                  |
| equal to                 | Rare variants (less than or  equal to 0.1 percent allele frequency in ethnically relevant population)                                      |
| at least                 | allele frequency in ethnically relevant population) shall have at least  three unique mutant heterozygous specimens tested.                |
| less than                | a point estimate for PPA or NPA of less than 99 percent (incorrect test results as compared to                                             |
| less than                | For the point estimates of PPA and NPA less than 100 percent, use the calculated estimates in the                                          |
| more than                | If the device is to be used at  more than one laboratory, different laboratories must be included in                                       |
| minimum                  | sensitivity data: Data must be generated demonstrating the minimum amount of DNA that will enable the test                                 |
| more than                | and matrix comparison data must be generated if more than one specimen type or anticoagulant can be tested                                 |
| maximum                  | a one-time visit with a cap on the maximum amount of time that a participant has to                                                        |
| minimum of               | meet the predefined primary endpoint criteria, including a minimum of a 90 percent or greater overall comprehension rate                   |
| greater                  | including a minimum of a 90 percent or greater overall comprehension rate (i.e. selection of the correct                                   |
| less than                | positive predictive value for a specific population is less than 50 percent and more than 5 percent, a                                     |
| more than                | specific population is less than 50 percent and more than 5 percent, a warning that reads &#8220;The positive                              |
| less than                | positive predictive value for a specific population is less than 5 percent, a warning that reads &#8220;The positive                       |
| exceeds                  | this section must show the device meets or exceeds  each of the following performance specifications:                                      |
| equal to                 | (i) The accuracy must be shown to be  equal to or greater than 99 percent for both PPA                                                     |
| greater than             | must be shown to be equal to or greater than  99 percent for both PPA and NPA.                                                             |
| less than                | a point estimate for PPA or NPA of less than 99 percent (incorrect test results as compared to                                             |
| exceed                   | (ii) Precision (reproducibility) performance must meet or  exceed  99 percent for both positive and negative results.                      |
| greater                  | study must obtain values of 90 percent or greater  user comprehension for each comprehension concept.                                      |
| prior to                 | or her doctor or other health care professional prior to  collection of a sample for testing.                                              |
| minimum                  | This section must, at a  minimum , be written in plain language understandable to                                                          |
| before                   | the test the user should be aware of before  purchase.                                                                                     |
| before                   | health care professional, genetic counselor, or equivalent professional before  getting the results of the test.                           |
| minimum                  | based on the variant frequency using either the minimum numbers of samples identified in this paragraph or,                                |
| minimum                  | based on the variant frequency using either the minimum numbers of samples identified in this paragraph or,                                |
| at least                 | samples representing the wild-type genotype must be tested. at least                                                                       |
| at least                 | in the relevant population) must be tested with at least  20 unique samples.                                                               |
| at least                 | in the relevant population) must be tested with at least  three unique samples.                                                            |
| at least                 | in a relevant population must be tested with at least  20 unique samples.                                                                  |
| at least                 | percent and &#8805;0.5 percent must be tested with at least  10 unique samples.                                                            |
| at least                 | relevant population &lt;0.5 percent must be tested with at least  three unique samples.                                                    |
| within                   | a frequency of &lt;0.5 percent are not found within the relevant population and homozygous samples are not                                 |
| after                    | accuracy study, use only the final results (i.e., after retesting the initial `no calls' or `invalid calls',                               |
| after                    | resulted in a `no call' or `invalid call' after retesting must not be included in the final                                                |
| less than                | point estimates of PA(DD|DD), PA(Dd|Dd) and PA(dd|dd) are less than 100 percent, use these point estimates in TPPV                         |
| more than                | If the device is to be used at  more than one laboratory, different laboratories must be included in                                       |
| minimum                  | sensitivity data: Data must be provided demonstrating the minimum amount of DNA that will enable the test                                  |
| more than                | and matrix comparison data must be generated if more than one specimen type can be tested with this                                        |
| minimum                  | Note that a  minimum requirement for the presence of the variant's effect                                                                  |
| before                   | the test the user should be aware of before  purchase.                                                                                     |
| before                   | health care professional, genetic counselor, or equivalent professional before  getting the results of the test.                           |
| prior to                 | education module to na&#239;ve user comprehension study participants prior to  their participation in the user comprehension study.        |
| within                   | identifies the appropriate general and variant-specific concepts contained within the material being tested in the user comprehension      |
| maximum                  | a one-time visit with a cap on the maximum amount of time that a participant has to                                                        |
| prior to                 | of the study, and be provided the labeling prior to  the start of the user comprehension study.                                            |
| minimum of               | meet the predefined primary endpoint criteria, including a minimum of a 90 percent or greater overall comprehension rate                   |
| greater                  | including a minimum of a 90 percent or greater overall comprehension rate (i.e., selection of the correct                                  |
| minimum of               | population; (C) Device reproducibility data generated, using a minimum of three sites, of which at least two sites                         |
| at least                 | using a minimum of three sites, of which at least two sites must be external sites, with two                                               |
| minimum of               | Each site must conduct a  minimum of three runs per operator over non-consecutive days evaluating                                          |
| minimum of               | Each site must conduct a  minimum of three runs per operator over non-consecutive days evaluating                                          |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 16.0 hour  | Test results obtained from short-term (less than 16 hours) incubation are used to determine the antimicrobial agent of choice to treat bacterial diseases.                                                                                                                                                                                                                                                                                           |
| 3.0 minute | When cytochrome oxidase is present, the swab turns a dark purple color within 3 minutes.                                                                                                                                                                                                                                                                                                                                                             |
| 3.0 year   | (iii) By July 31 of each calendar year, the results of the last 3 years of annual analytical reactivity testing must be included as part of the device's labeling.                                                                                                                                                                                                                                                                                   |
| 3.0 year   | If a device has not been on the market long enough for 3 years of annual analytical reactivity testing to have been conducted since the device received marketing authorization from FDA, then the results of every annual analytical reactivity testing since the device received marketing authorization from FDA must be included.                                                                                                                |
| 30.0 day   | (4) If one of the actions listed at section 564(b)(1)(A)-(D) of the Federal Food, Drug, and Cosmetic Act occurs with respect to an influenza viral strain, or if the Secretary of Health and Human Services (HHS) determines, under section 319(a) of the Public Health Service Act, that a disease or disorder presents a public health emergency, or that a public health emergency otherwise exists, with respect to an influenza viral strain:   |
|            |               (i) Within 30 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation, the manufacturer must have testing performed on the device with those viral samples in accordance with a standardized protocol considered and determined by FDA to be acceptable and appropriate.                                                                                                 |
| 60.0 day   | (ii) Within 60 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation and continuing until 3 years from that date, the results of the influenza emergency analytical reactivity testing, including the detailed information for the virus tested as described in the certificate of authentication, must be included as part of the device's labeling in a tabular format, either by: |
|            |               (A) Placing the results directly in the device's &#167;&#8201;809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where analytical reactivity testing data can be found, but separate from the annual analytical reactivity testing results; or                                                                                                                  |
|            |               (B) In a section of the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found.                                                                                                                                                                                                 |
| 3.0 year   | (ii) Within 60 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation and continuing until 3 years from that date, the results of the influenza emergency analytical reactivity testing, including the detailed information for the virus tested as described in the certificate of authentication, must be included as part of the device's labeling in a tabular format, either by: |
|            |               (A) Placing the results directly in the device's &#167;&#8201;809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where analytical reactivity testing data can be found, but separate from the annual analytical reactivity testing results; or                                                                                                                  |
|            |               (B) In a section of the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found.                                                                                                                                                                                                 |
| 5.0 day    | Colostrum is a substance excreted by the mammary glands during pregnancy and until production of breast milk begins 1 to 5 days after childbirth.                                                                                                                                                                                                                                                                                                    |
| 18.0 year  | Because the intended use population for Type 1 diabetes mellitus includes subjects less than 18 years old, samples from representative numbers of these subjects must be included.                                                                                                                                                                                                                                                                   |
| 1.0 year   | A minimum of 10 to 15 confirmed positive specimens must be obtained from more than 1 site, including relevant annotation, and, at 1 year or beyond, a SCID diagnosis by flow cytometry or clinically meaningful information regarding the status of the subject must be obtained.                                                                                                                                                                    |


## Condition

| Condition     | Context                                                                                                                                          |
|:--------------|:-------------------------------------------------------------------------------------------------------------------------------------------------|
| subject to    | of every device that is, or will be, subject to  the regulation.                                                                                 |
| unless        | Regulations are to chapter I of title 21, unless  otherwise noted.                                                                               |
| unless        | date shown in the regulation classifying the device unless the manufacturer has an approval under section 515                                    |
| unless        | Accordingly,  unless an effective date of the requirement for premarket                                                                          |
| unless        | the device before the device is commercially distributed unless  it is reclassified.                                                             |
| subject to    | is classified into class III and that is subject to the transitional provisions of section 520(l) of the                                         |
| where         | or the device is intended for lay use where the former intended use was by health care                                                           |
| when          | other than immunoglobulin G (IgG) or IgG assays when the results are not qualitative, or are used                                                |
| when          | by photometrically measuring changes in bacterial growth resulting when antimicrobial material is eluted from the disc into                      |
| subject to    | of many of the bacterial pathogens that are subject to  antimicrobial susceptibility tests.                                                      |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| if            | other suitable materials), each impregnated with a spec if ied, freeze-dried, viable microorganism, intended for medical purposes                |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| if not        | as chronic meningitis (inflammation of brain membranes) and, if not  treated, are usually fatal.                                                 |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| when          | in the assessment of patients with suspected sepsis when used in conjunction with clinical signs and symptoms                                    |
| if            | (4) Premarket not if ication submissions must include detailed documentation of a                                                                |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| if            | and symptoms consistent with acute hepatitis to determine if an individual has been previously infected with HAV,                                |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| when          | The positive percent agreement estimate for the device when testing for influenza A and influenza B must                                         |
| when          | The negative percent agreement estimate for the device when testing for influenza A and influenza B must                                         |
| when          | method: (A) The sensitivity estimate for the device when testing for influenza A must be at the                                                  |
| when          | The sensitivity estimate for the device  when testing for influenza B must be at the                                                             |
| when          | (B) The specificity estimate for the device  when testing for influenza A and influenza B must                                                   |
| when          | used to establish assay performance in clinical studies. when                                                                                    |
| where         | device in a separate section of the labeling where the analytical reactivity testing data can be found;                                          |
| where         | device in a separate section of the labeling where the analytical reactivity testing data can be found;                                          |
| if            | with respect to an influenza viral strain, or if the Secretary of Health and Human Services (HHS)                                                |
| if            | with respect to an influenza viral strain, or if the Secretary of Health and Human Services (HHS)                                                |
| until         | samples are available for test evaluation and continuing until 3 years from that date, the results of                                            |
| where         | device in a separate section of the labeling where analytical reactivity testing data can be found, but                                          |
| where         | device in a separate section of the labeling where analytical reactivity testing data can be found, but                                          |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| if            | brain and brain membranes) and is often fatal if  untreated.                                                                                     |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| when          | device aids in the diagnosis of bloodstream infections when used in conjunction with other clinical and laboratory                               |
| when          | an aid in the diagnosis of pulmonary tuberculosis when used in conjunction with clinical and other laboratory                                    |
| when          | and the selection of an initial treatment regimen when used in conjunction with clinical findings and other                                      |
| if            | frozen samples in the device performance studies, or if there is a device claim for the use                                                      |
| if            | Within-laboratory precision studies,  if appropriate, must include at least one antibiotic resistant                                             |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| when          | an individual patient with symptoms of acute gastroenteritis when the individual patient is epidemiologically linked to other                    |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| if            | infectious disease of the central nervous system which, if  undiagnosed, may be fatal.                                                           |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| if            | by lesions of the central nervous system, which if undetected and untreated may lead to brain defects,                                           |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| where         | to cause analytical error or affect assay performance. where                                                                                     |
| where         | domestic or international standard reference material and/or method. where                                                                       |
| where         | detailed documentation related to studies for surrogate controls. where                                                                          |
| if            | intended for quantitative or qualitative assays; (C) Stating if the material is a surrogate control; and (D)                                     |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| when          | to aid in the diagnosis of bloodstream infection when used in conjunction with clinical signs and symptoms                                       |
| when          | aid in the diagnosis of meningitis or encephalitis when used in conjunction with clinical signs and symptoms                                     |
| when          | aids in the diagnosis of respiratory viral infection when used in conjunction with other clinical and laboratory                                 |
| when          | infection aids in the diagnosis of gastrointestinal infection when used in conjunction with clinical evaluation and other                        |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| if            | (2) Premarket not if ication submissions must include the following information: (i)                                                             |
| if            | (2) Premarket not if ication submissions must include the following information: (i)                                                             |
| if            | The description must ident if y those control elements that are incorporated into                                                                |
| if            | Samples must also cover the assay measuring range,  if  applicable;                                                                              |
| if            | the determination of clinical sensitivity and clinical spec if icity using the test results (e.g., antibody status                               |
| if            | samples or pools from the associated assay spec if ic intended use population must be used; (D)                                                  |
| if            | samples or pools from the associated assay spec if ic intended use population must be used; (D)                                                  |
| if            | samples or pools from the associated assay spec if ic intended use population must be used; (D)                                                  |
| if            | samples or pools from the associated assay spec if ic intended use population must be used; (D)                                                  |
| if            | samples or pools from the associated assay spec if ic intended use population must be used; (D)                                                  |
| if            | samples or pools from the associated assay spec if ic intended use population must be used; (D)                                                  |
| if            | samples or pools from the associated assay spec if ic intended use population must be used; (D)                                                  |
| if            | this section and a summary of the results, if  applicable.                                                                                       |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| when          | stomach), and autoimmune connective tissue diseases (diseases resulting when  the body produces antibodies against its own tissues).             |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| until         | excreted by the mammary glands during pregnancy and until production of breast milk begins 1 to 5                                                |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| where         | This test aids in the diagnosis of diseases  where albumin levels may be depressed, e.g., nephrosis (disease                                     |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| when          | of plasma proteins found in the alpha-1 group when subjected to electrophoresis) in serum and other body                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| when          | of plasma proteins found in the alpha-2 group when subjected to electrophoresis) in serum and other body                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| when          | in the diagnosis of autoimmune disorders (disease produced when  the body's own tissues are injured by autoantibodies).                          |
| if            | controls for this device are: (1) Premarket not if ication submissions must include the following information: (i)                               |
| if            | external quality controls that are recommended or provided. if                                                                                   |
| if            | generated from samples covering the device measuring range, if  applicable.                                                                      |
| if            | description of value assignment of calibrators and controls, if  applicable.                                                                     |
| if            | blank, limit of detection, and limit of quantitation, if  applicable.                                                                            |
| when          | (F) Device instrument carryover data,  when  applicable.                                                                                         |
| where         | various storage times, temperatures, freeze-thaw, and transport conditions, where  appropriate.                                                  |
| if            | (J) Specimen matrix comparison data,  if more than one specimen type or anticoagulant can                                                        |
| when          | Magnetic Resonance Imaging),  when  appropriate, should always be taken into account                                                             |
| when          | Magnetic Resonance Imaging),  when  appropriate, should always be taken into account                                                             |
| if            | controls for this device are: (1) Premarket not if ication submissions must include the following information: (i)                               |
| where         | software applications and hardware-based devices that incorporate software where applicable; (D) A detailed description of appropriate internal  |
| if            | from patient samples covering the assay measuring range if applicable; (C) Information on traceability to a reference                            |
| if            | from patient samples covering the assay measuring range if applicable; (C) Information on traceability to a reference                            |
| if            | blank, limit of detection and limit of quantitation if  applicable;                                                                              |
|               |               (E) Device analytical spec                                                                                                         |
| when          | diseases or conditions; (F) Device instrument carryover data when applicable; (G) Device stability data including real-time stability            |
| where         | various storage times, temperatures, freeze-thaw, and transport conditions where appropriate; (I) Method comparison data generated by comparison |
| if            | must be used; (J) Specimen matrix comparison data if more than one specimen type or anticoagulant can                                            |
| when          | physical examination, and laboratory tests (e.g., serological tests), when  appropriate, should always be taken into account                     |
| when          | physical examination, and laboratory tests (e.g., serological tests), when  appropriate, should always be taken into account                     |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9.                                                         |
| subject to    | subpart E of part 807 of this chapter subject to  &#167;&#8201;866.9.                                                                            |
| if            | performed using thermocyclers from three independent thermocyler manufacturers. if                                                               |
| subject to    | subpart E of part 807 of this chapter subject to  the limitations in &#167;&#8201;866.9, except &#167;&#8201;866.9(c)(2).                        |
| if            | about how to obtain access to a board-cert if ied clinical molecular geneticist or equivalent to assist                                          |
| where         | prominent hyperlink to the manufacturer's public Web site where the manufacturer shall make the information identified in                        |
| if            | (A) Gene (or list of the genes  if more than one) and variants the test detects                                                                  |
| if            | Gynecologists (ACOG) guideline recommending testing of the spec if ic gene(s) and variants the test detects and                                  |
| where         | negative predictive value (NPV) for carrier status (and where  possible, for each variant) in each population.                                   |
| where         | &#8722; &#960;) + (1 &#8722; PPA*TC) * &#960;) where PPA and NPA described either in paragraph (b)(3)(ii)(A)(4)(i)                               |
| unless        | steps from the claimed specimen type or matrix, unless a separate extraction study for the claimed sample                                        |
| if            | The percentage of &#8220;no calls&#8221; or invalid calls,  if any, in the study must be provided as                                             |
| if            | type and matrix comparison data must be generated if more than one specimen type or anticoagulant can                                            |
| if            | concise summary of the results of the study. if                                                                                                  |
| where         | (3) The testing must follow a format  where users have limited time to complete the studies                                                      |
| where         | provide links to additional information pertaining to situations where the user is concerned about their test results                            |
| when          | the materials that will be available to them when  the test is marketed.                                                                         |
| where         | For example,  where applicable, the statement would have to include a                                                                            |
| where         | Or,  where applicable, the statement would have to include a                                                                                     |
| if            | recommended that you consult with a healthcare provider if you have any questions or concerns about your                                         |
| when          | For a positive result in an over-the-counter test when the positive predictive value for a specific population                                   |
| when          | For a positive result in an over-the-counter test when the positive predictive value for a specific population                                   |
| unless        | and any prepurchase page and test report generated, unless otherwise specified, must include: (i) A section addressed                            |
| if            | with their doctor or other health care professional if they have any questions or concerns about the                                             |
| where         | a hyperlink to the manufacturer's public Web site where the manufacturer shall make the information identified in                                |
| if            | to accept or decline to receive this spec if ic test result;                                                                                     |
|               |               (ii) Spec                                                                                                                          |
| when          | genetic test result; (iii) Professional guidelines that recommend when genetic testing for the associated target condition is                    |
| if            | when a particular gene and variant is detected. if                                                                                               |
| when          | guideline for the gene, variant, and disease, for when genetic testing should or should not be performed,                                        |
| when          | guideline for the gene, variant, and disease, for when genetic testing should or should not be performed,                                        |
| if            | professional guidelines are not available for these spec if ic gene(s) and variant(s).                                                           |
| when          | numbers of samples identified in this paragraph or, when determined appropriate and identified by FDA, a minimum                                 |
| if            | retesting the initial `no calls' or `invalid calls', if  required according to the instructions for use).                                        |
| where         | (ix) For variants  where the point estimates of PA(DD|DD), PA(Dd|Dd) and PA(dd|dd)                                                               |
| if            | variant (e.g., wild type, heterozygous, and homozygous) or, if  an alternative panel composition of specimens is ident                           |
| unless        | steps from the claimed specimen type or matrix, unless a separate extraction reproducibility study for the claimed                               |
| provided that | (3) Analytical specificity data: Data must be  provided that evaluates the effect of potential endogenous and exogenous                          |
| if            | type and matrix comparison data must be generated if more than one specimen type can be tested                                                   |
| if            | with 95 percent confidence intervals must be calculated. if                                                                                      |
| when          | as stated in paragraph (b)(3)(iii)(K)(2) of this section. when                                                                                   |
| if            | to accept or decline to receive this spec if ic test result;                                                                                     |
|               |               (ii) Spec                                                                                                                          |
| when          | genetic test result; (iii) Professional guidelines that recommend when genetic testing for the associated target condition is                    |
| where         | (iii) The testing must follow a format  where users have limited time to complete the studies                                                    |
| where         | (i) Prenatal testing; (ii) Determining predisposition for cancer where the result of the test may lead to                                        |
| subject to    | Food, Drug, and Cosmetic Act these devices are subject to the following restriction: A warning statement must be                                 |


## Entities

| Entities                                 | Context                                                                                                                                                                  |
|:-----------------------------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food                                     | Food  and Drugs.                                                                                                                                                         |
| Scope                                    | Scope .                                                                                                                                                                  |
| Test                                     | Test results are used to determine the antimicrobial agent                                                                                                               |
| Test                                     | Test results are used to determine the antimicrobial agent                                                                                                               |
| Test                                     | Test results obtained from short-term (less than 16 hours)                                                                                                               |
| Systems                                  | Special Controls Guidance Document: Antimicrobial Susceptibility Test (AST) Systems ; Guidance for Industry and FDA.&#8221; Culture medium                               |
| Guidance                                 | FDA's guidance document entitled &#8220;Class II Special Controls Guidance  Document: Antimicrobial Susceptibility Test (AST) Systems;                                   |
| Industry and FDA                         | Document: Antimicrobial Susceptibility Test (AST) Systems; Guidance for Industry and FDA .&#8221;                                                                        |
|                                          |               Culture medium for antimicrobial susceptibility tests.                                                                                                     |
| Culture                                  | Test (AST) Systems; Guidance for Industry and FDA.&#8221; Culture  medium for antimicrobial susceptibility tests.                                                        |
| Test                                     | Test results are used principally for the collection of                                                                                                                  |
| Anaerobic                                | Anaerobic  chamber.                                                                                                                                                      |
| Coagulase                                | Coagulase  plasma.                                                                                                                                                       |
| Coagulase                                | Coagulase plasma is a device that consists of freeze-dried                                                                                                               |
| Test                                     | Test results are used primarily as an aid in                                                                                                                             |
| Manual                                   | Manual  colony counter.                                                                                                                                                  |
| Petri                                    | Petri plates containing bacterial colonies to be counted are                                                                                                             |
| Indications                              | and the final report documenting support for the Indications for Use and the results of the statistical                                                                  |
| Multipurpose                             | Multipurpose  culture medium.                                                                                                                                            |
| Test                                     | Test results aid in the diagnosis of disease and                                                                                                                         |
| Test                                     | Test results aid in the diagnosis of disease and                                                                                                                         |
| Enriched                                 | Enriched  culture medium.                                                                                                                                                |
| Microbiological                          | Microbiological  assay culture medium.                                                                                                                                   |
| Test                                     | Test results aid in the diagnosis of disease resulting                                                                                                                   |
| Transport                                | Transport  culture medium.                                                                                                                                               |
| Culture                                  | Culture  medium for pathogenic  (a) Identification.                                                                                                                      |
| Neisseria                                | disease caused by bacteria belonging to the genus Neisseria , such as epidemic cerebrospinal meningitis, other meningococcal                                             |
| Oxidase                                  | Oxidase  screening test for gonorrhea.                                                                                                                                   |
| Neisseria                                | enzyme that is associated with certain bacteria including Neisseria  gonorrhoeae.                                                                                        |
| Automated                                | Automated  medium dispensing and stacking device.                                                                                                                        |
| Microbiological                          | Microbiological  incubator.                                                                                                                                              |
| Microbial                                | Microbial  growth monitor.                                                                                                                                               |
| Wood                                     | Wood 's fluorescent lamp.                                                                                                                                                |
| Microorganism                            | Microorganism  differentiation and identification device.                                                                                                                |
| Pathogenic                               | Pathogenic streptococci are associated with infections, such as sore                                                                                                     |
| Detection                                | and clinical performance studies: Analytical sensitivity (Limit of Detection ), reactivity, inclusivity, precision, reproducibility, interference, cross reactivity,     |
| Microbiological                          | Microbiological  specimen collection and transport device.                                                                                                               |
| Adenovirus                               | Adenovirus  serological reagents.                                                                                                                                        |
| Adenovirus                               | Adenovirus serological reagents are devices that consist of antigens                                                                                                     |
| Adenovirus                               | Adenovirus infections may cause pharyngitis (inflammation of the throat),                                                                                                |
| Arizona                                  | Arizona  spp.                                                                                                                                                            |
| Arizona                                  | consist of antisera and antigens used to identify Arizona  spp.                                                                                                          |
| Arizona                                  | Arizona  spp.                                                                                                                                                            |
| Aspergillus                              | Aspergillus  spp.                                                                                                                                                        |
| Aspergillus                              | in various serological tests to identify antibodies to Aspergillus  spp.                                                                                                 |
| Aspergillosis                            | Aspergillosis is a disease marked by inflammatory granulomatous (tumor-like)                                                                                             |
| Blastomycosis                            | Blastomycosis is a chronic granulomatous (tumor-like) disease, which may                                                                                                 |
| Bordetella                               | Bordetella  spp.                                                                                                                                                         |
| Bordetella                               | Bordetella  spp.                                                                                                                                                         |
| Brucella                                 | Brucella  spp.                                                                                                                                                           |
| Brucella                                 | antigens and antisera used for serological identification of Brucella  spp.                                                                                              |
| Brucella                                 | from clinical specimens or to identify antibodies to Brucella  spp.                                                                                                      |
| Malta                                    | in the diagnosis of brucellosis (e.g., undulant fever, Malta fever) caused by bacteria belonging to the genus                                                            |
| Campylobacter                            | Campylobacter fetus serological reagents are devices that consist of                                                                                                     |
| Campylobacter                            | Campylobacter fetus is a frequent cause of abortion in                                                                                                                   |
| Chlamydia                                | Chlamydia  serological reagents.                                                                                                                                         |
| Chlamydia                                | Chlamydia serological reagents are devices that consist of antigens                                                                                                      |
| Chlamydia                                | Chlamydia are the causative agents of psittacosis (a form                                                                                                                |
| Clostridium                              | Clostridium  difficile toxin gene amplification assay.                                                                                                                   |
| Clostridium                              | A  Clostridium difficile toxin gene amplification assay is a device                                                                                                      |
| Clostridium                              | A  Clostridium difficile toxin gene amplification assay is a device                                                                                                      |
| Clostridium                              | A  Clostridium difficile toxin gene amplification assay is a device                                                                                                      |
| Clostridium                              | the clinical laboratory diagnosis of CDI caused by Clostridium  difficile.                                                                                               |
| Clostridium                              | Toxin Gene Amplification Assays for the Detection of Clostridium difficile; Guideline for Industry and Food and Drug                                                     |
| Industry                                 | for the Detection of Clostridium difficile; Guideline for Industry and Food and Drug Administration Staff.&#8221; See &#167;&#8201;866.1(e)                              |
| Coccidioides                             | Coccidioides immitis serological reagents are devices that consist of                                                                                                    |
| Coccidioides                             | Coccidioides immitis serological reagents are devices that consist of                                                                                                    |
| Coccidioides                             | An infection with  Coccidioides immitis produces symptoms varying in severity from those                                                                                 |
| Corynebacterium                          | Corynebacterium  spp.                                                                                                                                                    |
| Corynebacterium                          | conjugated with a fluorescent dye used to identify Corynebacterium  spp.                                                                                                 |
| Corynebacterium                          | The principal human pathogen of this genus,  Corynebacterium  diphtheriae, causes diphtheria.                                                                            |
| Coxsackievirus                           | Coxsackievirus  serological reagents.                                                                                                                                    |
| Coxsackievirus                           | Coxsackievirus serological reagents are devices that consist of antigens                                                                                                 |
| Cryptococcus                             | Cryptococcus neoformans serological reagents are devices that consist of                                                                                                 |
| Cryptococcus                             | dye (immunofluorescent reagents) and are used to identify Cryptococcus neoformans directly from clinical specimens or from cultured                                      |
| Cryptococcosis                           | Cryptococcosis infections are found most often as chronic meningitis                                                                                                     |
| Cytomegalovirus                          | Cytomegalovirus  serological reagents.                                                                                                                                   |
| Cytomegalovirus                          | Cytomegalovirus serological reagents are devices that consist of antigens                                                                                                |
| Cytomegalic                              | Cytomegalic inclusion disease is a generalized infection of infants                                                                                                      |
| Cytomegalovirus                          | Cytomegalovirus infection has also been associated with acquired hemolytic                                                                                               |
| Echinococcus                             | Echinococcus  spp.                                                                                                                                                       |
| Echinococcus                             | serological reagents are devices that consist of  Echinococcus  spp.                                                                                                     |
| Echinococcus                             | used in serological tests to identify antibodies to Echinococcus  spp.                                                                                                   |
| Echinococcosis                           | Echinococcosis is characterized by the development of cysts in                                                                                                           |
| Echovirus                                | Echovirus  serological reagents.                                                                                                                                         |
| Echovirus                                | Echovirus serological reagents are devices that consist of antigens                                                                                                      |
| Endotoxin                                | Endotoxin  assay.                                                                                                                                                        |
| Device                                   | Device to detect and measure non-microbial analyte(s) in human                                                                                                           |
| Detection                                | analytical studies, such as, analytical sensitivity (Limit of Detection , Limit of Blank, and Limit of Quantitation),                                                    |
| Blank                                    | as, analytical sensitivity (Limit of Detection, Limit of Blank , and Limit of Quantitation), precision, reproducibility, analytical                                      |
| Quantitation                             | of Detection, Limit of Blank, and Limit of Quantitation ), precision, reproducibility, analytical measuring range, interference, cross-reactivity,                       |
| Indications                              | analysis plan), study report documenting support for the Indications  for Use(s), and results of all statistical analyses.                                               |
| Entamoeba                                | Entamoeba histolytica serological reagents are devices that consist of                                                                                                   |
| Enterovirus                              | Enterovirus  nucleic acid assay.                                                                                                                                         |
| Enterovirus RNA                          | Nucleic Acid Amplification Assay for the Detection of Enterovirus RNA .&#8221; See &#167;&#8201;866.1(e) for the availability of this                                    |
| African                                  | Burkitt's lymphoma (a tumor of the jaw in African  children and young adults) and postnasal carcinoma (cancer).                                                          |
| Equine                                   | Equine  encephalomyelitis virus serological reagents.                                                                                                                    |
| Equine                                   | Equine encephalomyelitis virus serological reagents are devices that consist                                                                                             |
| Equine                                   | Equine encephalomyelitis viruses are transmitted to humans by the                                                                                                        |
| Erysipelothrix                           | Erysipelothrix rhusiopathiae serological reagents are devices that consist of                                                                                            |
| Escherichia                              | Escherichia coli serological reagents are devices that consist of                                                                                                        |
| Escherichia                              | Additionally, some of these reagents consist of  Escherichia coli antisera conjugated with a fluorescent dye used                                                        |
| Escherichia                              | Additionally, some of these reagents consist of  Escherichia coli antisera conjugated with a fluorescent dye used                                                        |
| Flavobacterium                           | Flavobacterium  spp.                                                                                                                                                     |
| Flavobacteriuim                          | and antisera used in serological tests to identify Flavobacteriuim  spp.                                                                                                 |
| Flavobacterium                           | Flavobacterium meningosepticum is highly virulent for the newborn, in                                                                                                    |
| Francisella                              | Francisella tularensis serological reagents are devices that consist of                                                                                                  |
| Francisella                              | Francisella tularensis serological reagents are devices that consist of                                                                                                  |
| Francisella                              | Francisella tularensis serological reagents are devices that consist of                                                                                                  |
| Francisella                              | a fluorescent dye (immunofluorescent reagents) used to identify Francisella  tularensis directly from clinical specimens.                                                |
| Francisella                              | aids in the diagnosis of tularemia caused by Francisella  tularensis and provides epidemiological information on this disease.                                           |
| Tularemia                                | Tularemia is a desease principally of rodents, but may                                                                                                                   |
| Gonococcal                               | Gonococcal  antibody test (GAT).                                                                                                                                         |
| Neisseria                                | agglutination, indirect fluorescent antibody, or radioimmunoassay, antibodies to Neisseria gonorrhoeae in sera of asymptomatic females at low                            |
| Haemophilus                              | Haemophilus  spp.                                                                                                                                                        |
| Haemophilus                              | that are used in serological tests to identify Haemophilus  spp.                                                                                                         |
| Haemophilus                              | Diseases most often caused by  Haemophilus  spp.                                                                                                                         |
| Herpes                                   | Herpes  simplex virus serological assays.                                                                                                                                |
| Herpes                                   | Herpes simplex virus serological assays are devices that consist                                                                                                         |
| Herpes                                   | Herpes simplex viral infections range from common and mild                                                                                                               |
| Neonatal                                 | Neonatal herpes virus infections range from a mild infection                                                                                                             |
| Guidance                                 | The special control is &#8220; Guidance for Industry and FDA Staff: Class II Special                                                                                     |
| Industry                                 | The special control is &#8220;Guidance for  Industry and FDA Staff: Class II Special Controls Guidance                                                                   |
| Histoplasma                              | Histoplasma capsulatum serological reagents are devices that consist of                                                                                                  |
| Histoplasma                              | Histoplasma capsulatum serological reagents are devices that consist of                                                                                                  |
| Histoplasma                              | Additionally, some of these reagents consist of  Histoplasma capsulatum antisera conjugated with a fluorescent dye (immunofluorescent                                    |
| Histoplasma                              | Additionally, some of these reagents consist of  Histoplasma capsulatum antisera conjugated with a fluorescent dye (immunofluorescent                                    |
| Influenza                                | Influenza  virus antigen detection test system.                                                                                                                          |
| Health                                   | influenza viral strain, or if the Secretary of Health and Human Services (HHS) determines, under section 319(a)                                                          |
| Influenza                                | Influenza  virus serological reagents.                                                                                                                                   |
| Influenza                                | Influenza virus serological reagents are devices that consist of                                                                                                         |
| Influenza                                | Influenza is an acute respiratory tract disease, which is                                                                                                                |
| Klebsiella                               | Klebsiella  spp.                                                                                                                                                         |
| Leptospira                               | Leptospira  spp.                                                                                                                                                         |
| Leptospira                               | used in serological tests to identify antibodies to Leptospira  spp.                                                                                                     |
| Leptospira                               | Leptospira infections range from mild fever-producing illnesses to severe                                                                                                |
| Listeria                                 | Listeria  spp.                                                                                                                                                           |
| Listeria                                 | and antisera used in serological tests to identify Listeria  spp.                                                                                                        |
| Listeria                                 | Additionally, some of these reagents consist of  Listeria  spp.                                                                                                          |
| Listeria                                 | a fluorescent dye (immunofluorescent reagents) used to identify Listeria  spp.                                                                                           |
| Listeria                                 | disease caused by bacteria belonging to the genus Listeria , and provides epidemiological information on diseases caused                                                 |
| Listeria                                 | Listeria monocytogenes, the most common human pathogen of this                                                                                                           |
| Lymphocytic                              | Lymphocytic  choriomeningitis virus serological reagents.                                                                                                                |
| Lymphocytic                              | Lymphocytic choriomeningitis virus serological reagents are devices that consist                                                                                         |
| Lymphocytic                              | Lymphocytic choriomeningitis viruses usually cause a mild cerebral meningitis                                                                                            |
| Mass                                     | Mass spectrometer system for clinical use for the identification                                                                                                         |
| Multiplexnucleic                         | microorganisms and resistance markers from positive blood cultures. Multiplexnucleic                                                                                     |
| Mycobacterium                            | Mycobacterium tuberculosis immunofluorescent reagents are devices that consist of                                                                                        |
| Mycobacterium                            | Mycobacterium tuberculosis immunofluorescent reagents are devices that consist of                                                                                        |
| Mycobacterium                            | Mycobacterium tuberculosis is the common causative organism in human                                                                                                     |
| Nucleic                                  | Nucleic acid-based in vitro diagnostic devices for the detection                                                                                                         |
| Mycobacterium                            | in vitro diagnostic devices for the detection of Mycobacterium  tuberculosis complex in respiratory specimens.                                                           |
| Nucleic                                  | Nucleic acid-based in vitro diagnostic devices for the detection                                                                                                         |
| Mycobacterium                            | in vitro diagnostic devices for the detection of Mycobacterium tuberculosis complex in respiratory specimens are qualitative nucleic                                     |
| Mycobacterium                            | in vitro diagnostic devices for the detection of Mycobacterium tuberculosis complex in respiratory specimens are qualitative nucleic                                     |
| Respiratory                              | Respiratory specimens may include sputum (induced or expectorated), bronchial                                                                                            |
| Vitro                                    | &#8220;Class II Special Controls Guideline: Nucleic Acid-Based In Vitro Diagnostic Devices for the Detection of Mycobacterium tuberculosis                               |
| Mycobacterium                            | In Vitro Diagnostic Devices for the Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens.&#8221; For availability of                                 |
| Respiratory Specimens                    | for the Detection of Mycobacterium tuberculosis Complex in Respiratory Specimens .&#8221; For availability of the guideline document, see                                |
| Nucleic                                  | Nucleic acid-based in vitro diagnostic devices for the detection                                                                                                         |
| Mycobacterium                            | in vitro diagnostic devices for the detection of Mycobacterium tuberculosis complex (MTB-complex) and the genetic mutations associated                                   |
| Nucleic                                  | Nucleic acid-based in vitro diagnostic devices for the detection                                                                                                         |
| Mycobacterium                            | in vitro diagnostic devices for the detection of Mycobacterium tuberculosis complex (MTB-complex) and the genetic mutations associated                                   |
| Vitro                                    | &#8220;Class II Special Controls Guideline: Nucleic Acid-Based In Vitro Diagnostic Devices for the Detection of Mycobacterium tuberculosis                               |
| Mycobacterium                            | In Vitro Diagnostic Devices for the Detection of Mycobacterium tuberculosis Complex and Genetic Mutations Associated with Antibiotic                                     |
| Respiratory Specimens                    | and Genetic Mutations Associated with Antibiotic Resistance in Respiratory Specimens ,&#8221; which addresses the mitigation of risks specific                           |
| Extraction                               | Extraction methods must parallel those used in devices for                                                                                                               |
| Detection                                | (B) Analytical studies that analyze:                                                                                                                                     |
|                                          |               (1) Limit of  Detection .                                                                                                                                  |
| Limit                                    | Limit of Detection must be determined in the most                                                                                                                        |
| Isolate                                  | Isolate strain characterization must be determined using standardized reference                                                                                          |
| Clinical                                 | Clinical studies must compare device results to both phenotypic                                                                                                          |
| Mycoplasma                               | Mycoplasma  spp.                                                                                                                                                         |
| Mycoplasma                               | used in serological tests to identify antibodies to Mycoplasma  spp.                                                                                                     |
| Mycoplasma                               | Additionally, some of these reagents consist of  Mycoplasma  spp.                                                                                                        |
| Mycoplasma                               | Mycoplasma  spp.                                                                                                                                                         |
| Mumps                                    | Mumps  virus serological reagents.                                                                                                                                       |
| Mumps                                    | Mumps virus serological reagents consist of antigens and antisera                                                                                                        |
| Mumps                                    | Mumps is an acute contagious disease, particularly in children,                                                                                                          |
| Neisseria                                | Neisseria  spp.                                                                                                                                                          |
| Neisseria                                | and antisera used in serological tests to identify Neisseria  spp.                                                                                                       |
| Neisseria                                | Additionally, some of these reagents consist of  Neisseria  spp.                                                                                                         |
| Neisseria                                | may be used to detect the presence of Neisseria  spp.                                                                                                                    |
| Neisseria                                | disease caused by bacteria belonging to the genus Neisseria , such as epidemic cerebrospinal meningitis, meningococcal disease,                                          |
| Norovirus                                | Norovirus  serological reagents.                                                                                                                                         |
| Norovirus                                | Norovirus serological reagents are devices that consist of antigens                                                                                                      |
| Parainfluenza                            | Parainfluenza  virus serological reagents.                                                                                                                               |
| Parainfluenza                            | Parainfluenza virus serological reagents are devices that consist of                                                                                                     |
| Parainfluenza                            | Parainfluenza viruses cause a variety of respiratory illnesses ranging                                                                                                   |
| Plasmodium                               | Plasmodium  species antigen detection assays.                                                                                                                            |
| Plasmodium                               | the four malaria species capable of infecting humans: Plasmodium  falciparum,                                                                                            |
| Plasmodium                               | the four malaria species capable of infecting humans: Plasmodium  falciparum,                                                                                            |
| Plasmodium                               | the four malaria species capable of infecting humans: Plasmodium  falciparum,                                                                                            |
| Plasmodium                               | the four malaria species capable of infecting humans: Plasmodium  falciparum,                                                                                            |
| Poliovirus                               | Poliovirus  serological reagents.                                                                                                                                        |
| Poliovirus                               | Poliovirus serological reagents are devices that consist of antigens                                                                                                     |
| Poliomyelitis                            | Poliomyelitis is an acute infectious disease which in its                                                                                                                |
| Proteus                                  | Proteus  spp.                                                                                                                                                            |
| Test                                     | Test results aid in the diagnosis of diseases caused                                                                                                                     |
| Rickettsia                               | Rickettsia are generally transmitted by arthropods (e.g., ticks and                                                                                                      |
| Pseudomonas                              | Pseudomonas  spp.                                                                                                                                                        |
| Pseudomonas                              | a fluorescent dye (immunofluorescent reagents), used to identify Pseudomonas  spp.                                                                                       |
| Pseudomonas                              | Pseudomonas aeruginosa is a major cause of hospital-acquired infections,                                                                                                 |
| Pseudomonas                              | Pseudomonas  pseudomallei causes melioidosis, a chronic pneumonia.                                                                                                       |
| Rabiesvirus                              | Rabiesvirus  immunoÂ­fluorescent reagents.                                                                                                                                |
| Rabiesvirus                              | Rabiesvirus immunofluorescent reagents are devices that consist of rabiesvirus                                                                                           |
| Reovirus                                 | Reovirus  serological reagents.                                                                                                                                          |
| Reovirus                                 | Reovirus serological reagents are devices that consist of antigens                                                                                                       |
| Respiratory                              | Respiratory  syncytial virus serological reagents.                                                                                                                       |
| Respiratory                              | Respiratory syncytial virus serological reagents are devices that consist                                                                                                |
| Respiratory                              | Respiratory syncytial viruses cause a number of respiratory tract                                                                                                        |
| Rhinovirus                               | Rhinovirus  serological reagents.                                                                                                                                        |
| Rhinovirus                               | Rhinovirus serological reagents are devices that consist of antigens                                                                                                     |
| Rickettsia                               | Rickettsia  serological reagents.                                                                                                                                        |
| Rickettsia                               | Rickettsia serological reagents are devices that consist of antigens                                                                                                     |
| Rickettsia                               | Rickettsia are generally transmitted by arthropods (e.g., ticks and                                                                                                      |
| Rubella                                  | Rubella  virus serological reagents.                                                                                                                                     |
| Rubella                                  | Rubella virus serological reagents are devices that consist of                                                                                                           |
| German                                   | identification aids in the diagnosis of rubella ( German measles) or confirmation of a person's immune status                                                            |
| German                                   | identification aids in the diagnosis of rubella ( German measles) or confirmation of a person's immune status                                                            |
| Newborns                                 | Newborns infected in the uterus with rubella virus may                                                                                                                   |
| Limitations                              | Diseases, December 1994,&#8221; (iii) D13 &#8220;Agglutination Characteristics, Methodology, Limitations , and Clinical Validation, October 1993,&#8221; (iv) EP5        |
| Rubeola                                  | Rubeola  (measles) virus serological reagents.                                                                                                                           |
| Rubeola                                  | Rubeola (measles) virus serological reagents are devices that consist                                                                                                    |
| Measles                                  | Measles is an acute, highly infectious disease of the                                                                                                                    |
| Salmonella                               | Salmonella  spp.                                                                                                                                                         |
| Salmonellosis                            | Salmonellosis is characterized by high grade fever (&#8220;enteric fever&#8221;),                                                                                        |
| Schistosoma                              | Schistosoma  spp.                                                                                                                                                        |
| Schistosoma                              | used in serological tests to identify antibodies to Schistosoma  spp.                                                                                                    |
| Schistosomiasis                          | Schistosomiasis is characterized by a variety of acute and                                                                                                               |
| Acute                                    | Acute infection is marked by fever, allergic symptoms, and                                                                                                               |
| Chronic                                  | Chronic effects are usually severe and are caused by                                                                                                                     |
| Serratia                                 | Serratia  spp.                                                                                                                                                           |
| Serratia                                 | and antisera used in serological tests to identify Serratia  spp.                                                                                                        |
| Serratia                                 | Serratia  spp.                                                                                                                                                           |
| Shigella                                 | Shigella  spp.                                                                                                                                                           |
| Shigellosis                              | Shigellosis is characterized by abdominal pain, cramps, diarrhea, and                                                                                                    |
| Sporothrix                               | Sporothrix schenckii serological reagents are devices that consist of                                                                                                    |
| Sporothrichosis                          | Sporothrichosis is a chronic tumorlike infection primarily of the                                                                                                        |
| Certain                                  | Certain strains of Staphylococcus aureus produce an enterotoxin while                                                                                                    |
| Streptococcus                            | Streptococcus  spp.                                                                                                                                                      |
| Streptococcus                            | reagents are devices used to identify antibodies to Streptococcus  spp.                                                                                                  |
| Pathogenic                               | Pathogenic streptococci are associated with infections, such as sore                                                                                                     |
| Streptococcus                            | Streptococcus  spp.                                                                                                                                                      |
| Pathogenic                               | Pathogenic streptococci are associated with infections, such as sore                                                                                                     |
| Toxoplasma                               | Toxoplasma gondii serological reagents are devices that consist of                                                                                                       |
| Toxoplasma                               | Toxoplasma gondii serological reagents are devices that consist of                                                                                                       |
| Treponema                                | Treponema pallidum nontreponemal test reagents are devices that consist                                                                                                  |
| Treponema                                | Treponema pallidum treponemal test reagents are devices that consist                                                                                                     |
| Treponema                                | other treponemal tests used to identify antibodies to Treponema  pallidum directly from infecting treponemal organisms in serum.                                         |
| Trichinella                              | Trichinella spiralis serological reagents are devices that consist of                                                                                                    |
| Trichinella                              | Trichinella spiralis serological reagents are devices that consist of                                                                                                    |
| Trichinosis                              | Trichinosis is caused by ingestion of undercooked, infested meat,                                                                                                        |
| Trichomonas                              | Nucleic Acid Amplification Assays for the Detection of Trichomonas vaginalis; Guideline for Industry and Food and Drug                                                   |
| Industry                                 | for the Detection of Trichomonas vaginalis; Guideline for Industry and Food and Drug Administration Staff.&#8221; See &#167;&#8201;866.1(e)                              |
| Trypanosoma                              | Trypanosoma  spp.                                                                                                                                                        |
| Trypanosoma                              | used in serological tests to identify antibodies to Trypanosoma  spp.                                                                                                    |
| Trypanosomiasis                          | Trypanosomiasis in adults is a chronic disease characterized by                                                                                                          |
| Central                                  | Central nervous system involvement produces typical sleeping sickness syndrome:                                                                                          |
| Chagas                                   | Chagas disease, an acute form of trypanosomiasis in children,                                                                                                            |
| Varicella                                | Varicella (chicken pox) is a mild, highly infectious disease,                                                                                                            |
| Zoster                                   | Zoster (shingles) is the recurrent form of the disease,                                                                                                                  |
| Zoster                                   | Zoster is the response (characterized by a rash) of                                                                                                                      |
| Assayed                                  | Assayed  quality control material for clinical microbiology assays.                                                                                                      |
| Vibrio                                   | Vibrio cholerae serological reagents are devices that are used                                                                                                           |
| Cholera                                  | Cholera is an acute infectious disease characterized by severe                                                                                                           |
| West                                     | West  Nile virus serological reagents.                                                                                                                                   |
| West                                     | West Nile virus serological reagents are devices that consist                                                                                                            |
| West Nile Virus                          | Document: Serological Reagents for the Laboratory Diagnosis of West Nile Virus .&#8221; See &#167;&#8201;866.1(e) for the availability of this                           |
| Dengue                                   | Dengue  virus serological reagents.                                                                                                                                      |
| Dengue                                   | Dengue virus serological reagents are devices that consist of                                                                                                            |
| Dengue                                   | Dengue  virus nucleic acid amplification test reagents.                                                                                                                  |
| Dengue                                   | Dengue virus nucleic acid amplification test reagents are devices                                                                                                        |
| Vitro HIV Drug Resistance Genotype Assay | entitled &#8220;Class II Special Controls Guidance Document: In Vitro HIV Drug Resistance Genotype Assay .&#8221; See &#167;&#8201;866.1(e) for the availability of this |
| Nucleic                                  | Nucleic acid-based device for the amplification, detection, and identification                                                                                           |
| Device                                   | Device to detect and identify microbial pathogen nucleic acids                                                                                                           |
| Rhinovirus                               | and Parainfluenza 3 virus; (5) Human Metapneumovirus; (6) Rhinovirus ; and                                                                                               |
|                                          |               (7) Adenovirus.                                                                                                                                            |
| Molecular                                | Stabilization and Purification System for RT-PCR Used in Molecular Diagnostic Testing).&#8221; See &#167;&#8201;866.1(e) for the availability of                         |
| Immunoelectrophoresis                    | Immunoelectrophoresis  equipment.                                                                                                                                        |
| Immunoelectrophoresis                    | Immunoelectrophoresis equipment for clinical use with its electrical power                                                                                               |
| Immunoelectrophoresis                    | Immunoelectrophoresis is a procedure in which a complex protein                                                                                                          |
| Ouchterlony                              | Ouchterlony  agar plate.                                                                                                                                                 |
| U.S                                      | performance established by comparing device results at multiple U.S . sites to the clinical diagnostic standard used                                                     |
| United States                            | to the clinical diagnostic standard used in the United States , using patient samples from the assay-specific intended                                                   |
| Radial                                   | Radial  immunodiffusion plate.                                                                                                                                           |
| Rocket                                   | Rocket  immunoelectroÂ­phoresis equipment.                                                                                                                                |
| Rocket                                   | Rocket immunoelectrophoresis equipment for clinical use is a device                                                                                                      |
| Support                                  | Support  gel.                                                                                                                                                            |
| Human                                    | Human  allotypic marker immunological test system.                                                                                                                       |
| Antimitochondrial                        | Antimitochondrial  antibody immunological test system.                                                                                                                   |
| Antiparietal                             | Antiparietal  antibody immunological test system.                                                                                                                        |
| Gastric                                  | Gastric parietal cells are those cells located in the                                                                                                                    |
| Immunoglobulin                           | Immunoglobulin molecules normally consist of pairs of polypeptide chains                                                                                                 |
| Breast                                   | Breast  milk immunological test system.                                                                                                                                  |
| Fecal                                    | Fecal  calprotectin immunological test system.                                                                                                                           |
| Carbonic                                 | Carbonic  anhydrase B and C immunological test system.                                                                                                                   |
| Ceruloplasmin                            | Ceruloplasmin  immunologÂ­ical test system.                                                                                                                               |
| Cohn                                     | Cohn  fraction II immunologÂ­ical test system.                                                                                                                            |
| Colostrum                                | Colostrum  immunological test system.                                                                                                                                    |
| Colostrum                                | Colostrum is a substance excreted by the mammary glands                                                                                                                  |
| C2, C3, C4, C5, C6, C7, C8, and C9       | by immunochemical techniques complement components C1q, C1r, C1s, C2, C3, C4, C5, C6, C7, C8, and C9 , in serum, other body fluids, and tissues.                         |
| Properdin                                | Properdin  factor B immunoÂ­logical test system.                                                                                                                          |
| XIII, A, S                               | Factor  XIII, A, S , immunoÂ­logical test system.                                                                                                                         |
| Ferritin                                 | Ferritin  immunological test system.                                                                                                                                     |
| Cohn                                     | Cohn  fraction IV immunoÂ­logical test system.                                                                                                                            |
| Cohn                                     | Cohn  fraction V immunoÂ­logical test system.                                                                                                                             |
| Free                                     | Free  secretory component immunoÂ­logical test system.                                                                                                                    |
| Haptoglobin                              | Haptoglobin  immunological test system.                                                                                                                                  |
| Hemoglobin                               | Hemoglobin  immunological test system.                                                                                                                                   |
| Hemopexin                                | Hemopexin  immunological test system.                                                                                                                                    |
| Hypersensitivity                         | Hypersensitivity  pneumonitis immunological test system.                                                                                                                 |
| G, M, D, and E                           | Immunoglobulins A,  G, M, D, and E  immunological test system.                                                                                                           |
| G, M, D, and E                           | An immunoglobulins A,  G, M, D, and E immunological test system is a device that consists                                                                                |
| G, M, D                                  | An immunoglobulins A,  G, M, D , and E immunological test system is a                                                                                                    |
| Fab                                      | Measurement of  Fab fragments of immunoglobulin G aids in the diagnosis                                                                                                  |
| Immunoglobulin                           | Immunoglobulin  (light chain specific) immunological test system.                                                                                                        |
| Lactic                                   | Lactic  dehydrogenase immunological test system.                                                                                                                         |
| Lactoferrin                              | Lactoferrin  immunological test system.                                                                                                                                  |
| Tangier                                  | of alpha-1-lipoprotein may aid in the diagnosis of Tangier  disease (a hereditary disorder of fat metabolism).                                                           |
| Infectious                               | Infectious  mononucleosis immunological test system.                                                                                                                     |
| Lyme                                     | be limited to the following: Multiple sclerosis, stroke, Lyme disease, shingles, syphilis, human immunodeficiency virus, hepatitis B,                                    |
| Zinc                                     | Zinc  transporter 8 autoantibody immunological test system.                                                                                                              |
| Myoglobin                                | Myoglobin  immunological test system.                                                                                                                                    |
| Whole                                    | Whole  human plasma or serum immunological test system.                                                                                                                  |
| Prothrombin                              | Prothrombin  immunological test system.                                                                                                                                  |
| Radioallergosorbent                      | Radioallergosorbent  (RAST) immunological test system.                                                                                                                   |
| Tryptase                                 | Tryptase  test system.                                                                                                                                                   |
| Rheumatoid                               | Rheumatoid  factor immunoÂ­logical test system.                                                                                                                           |
| Crohn                                    | cerevisiae antibodies may aid in the diagnosis of Crohn 's disease.                                                                                                      |
| Guidance                                 | The special control is FDA's &#8220; Guidance for Industry and FDA Reviewers: Class II Special                                                                           |
| Industry                                 | The special control is FDA's &#8220;Guidance for  Industry and FDA Reviewers: Class II Special Control Guidance                                                          |
| Seminal                                  | Anti-Saccharomyces cerevisiae (S. cerevisiae) Antibody (ASCA) Premarket Notifications.&#8221; Seminal  fluid (sperm) immunological test system.                          |
| Systemic                                 | Systemic  lupus erythemaÂ­tosus immunological test system.                                                                                                                |
| Total                                    | Total  spinal fluid immunoÂ­logical test system.                                                                                                                          |
| Thyroid                                  | Thyroid  autoantibody immunological test system.                                                                                                                         |
| Transferrin                              | Transferrin  immunological test system.                                                                                                                                  |
| Cystic                                   | Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation detection                                                                                       |
| Newborn                                  | Newborn  screening test for severe combined immunodeficiency disorder (SCID).                                                                                            |
| Sample                                   | Sample reports must include the scale used in reporting                                                                                                                  |
| Point                                    | Point estimates together with two-sided 95 percent confidence intervals                                                                                                  |
| Data                                     | Data must include the retest rate, the false positive                                                                                                                    |
| Identical                                | Identical specimens from the same sample panel must be                                                                                                                   |
| Total                                    | Total variation must be partitioned into the sum of                                                                                                                      |
| Data                                     | Data demonstrating the concordance between results across different filter                                                                                               |
| Study                                    | Study  acceptance criteria must be provided and followed; and                                                                                                            |
| Study                                    | Study  acceptance criteria must be provided and followed.                                                                                                                |
| Test                                     | SCID.&#8221;; (ii) A warning statement that reads &#8220; Test results are intended to be used in conjunction                                                            |
| Autosomal                                | Autosomal  recessive carrier screening gene mutation detection system.                                                                                                   |
| Autosomal                                | Autosomal recessive carrier screening gene mutation detection system is                                                                                                  |
| Autosomal                                | Autosomal recessive carrier screening gene mutation detection system must                                                                                                |
| Gynecologists                            | Genetics (ACMG) or American Congress of Obstetricians and Gynecologists (ACOG) guideline recommending testing of the specific gene(s)                                    |
| Accuracy                                 | the performance characteristics of the device, including: (A) Accuracy (method comparison) of study results for each claimed                                             |
| Performance                              | Performance criteria for both the comparator method and device                                                                                                           |
| Clinical                                 | Clinical specimens must include both homozygous wild type and                                                                                                            |
| Rare                                     | Rare variants (less than or equal to 0.1 percent                                                                                                                         |
| Accuracy                                 | Accuracy measures generated from clinical specimens versus contrived samples                                                                                             |
| Point                                    | Point estimate of PPA should be calculated as the                                                                                                                        |
| Point                                    | Point estimates should be calculated along with 95 percent                                                                                                               |
| Performance                              | Performance  criteria must be predefined.                                                                                                                                |
| Data                                     | Data  supporting such claims must be described.                                                                                                                          |
| Test                                     | Test reports given to users must: Define the condition                                                                                                                   |
| Genetic                                  | Genetic  health risk assessment system.                                                                                                                                  |
| Performance                              | Performance criteria for both the comparator method and the                                                                                                              |
| Rare                                     | Rare variants (&#8804;0.1 percent variant frequency in the relevant                                                                                                      |
| Dd                                       | an example, for samples with different genotypes DD, Dd , and dd, the following table represents data                                                                    |
| Accuracy                                 | Accuracy results generated from clinical specimens versus contrived samples                                                                                              |
| Data                                     | Data  supporting such claims must be provided.                                                                                                                           |
| Note                                     | Note that a minimum requirement for the presence of                                                                                                                      |
| Test                                     | Test reports in the user comprehension study given to                                                                                                                    |
| Tumor                                    | Tumor markers must comply with the following special controls:                                                                                                           |
| Gene                                     | Gene  expression profiling test system for breast cancer prognosis.                                                                                                      |
| Ovarian                                  | Ovarian  adnexal mass assessment score test system.                                                                                                                      |


## Date

| Date       | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|:-----------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1976-05-28 | (b) Any new, not substantially equivalent, device introduced into commercial distribution on or after May 28, 1976, including a device formerly marketed that has been substantially altered, is classified by statute (section 513(f) of the act) into class III without any grace period and FDA must have issued an order approving a PMA or declaring completed a PDP for the device before the device is commercially distributed unless it is reclassified. |
| 1976-05-28 | Accordingly, the regulation for such a class III device states that as of the enactment date of the amendments, May 28, 1976, the device must have an approval under section 515 of the act before commercial distribution.                                                                                                                                                                                                                                       |
| 1976-05-28 | Accordingly, the regulation for such a class III transitional device states that as of the enactment date of the amendments, May 28, 1976, the device must have an approval under section 515 of the act before commercial distribution.                                                                                                                                                                                                                          |
| 1976-05-28 | As of May 28, 1976, an approval under section 515 of the act is required before this device may be commercially distributed.                                                                                                                                                                                                                                                                                                                                      |
| 1976-05-28 | As of May 28, 1976, an approval under section 515 of the act is required before this device may be commercially distributed.                                                                                                                                                                                                                                                                                                                                      |
| 2018-07-31 | (iii) By July 31 of each calendar year, the results of the last 3 years of annual analytical reactivity testing must be included as part of the device's labeling.                                                                                                                                                                                                                                                                                                |
| 2018-09-01 | (ii) Within 60 days from the date that FDA notifies manufacturers that characterized viral samples are available for test evaluation and continuing until 3 years from that date, the results of the influenza emergency analytical reactivity testing, including the detailed information for the virus tested as described in the certificate of authentication, must be included as part of the device's labeling in a tabular format, either by:              |
|            |               (A) Placing the results directly in the device's &#167;&#8201;809.10(b) of this chapter compliant labeling that physically accompanies the device in a separate section of the labeling where analytical reactivity testing data can be found, but separate from the annual analytical reactivity testing results; or                                                                                                                               |
|            |               (B) In a section of the device's label or in other labeling that physically accompanies the device, prominently providing a hyperlink to the manufacturer's public Web site where the analytical reactivity testing data can be found.                                                                                                                                                                                                              |
| 1997-10-01 | The special controls for this device are:                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (1) National Committee for Clinical Laboratory Standards':                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (i) 1/LA6 &#8220;Detection and Quantitation of Rubella IgG Antibody: Evaluation and Performance Criteria for Multiple Component Test Products, Speciment Handling, and Use of the Test Products in the Clinical Laboratory, October 1997,&#8221;                                                                                                                                                                                                    |
|            |               (ii) 1/LA18 &#8220;Specifications for Immunological Testing for Infectious Diseases, December 1994,&#8221;                                                                                                                                                                                                                                                                                                                                          |
|            |               (iii) D13 &#8220;Agglutination Characteristics, Methodology, Limitations, and Clinical Validation, October 1993,&#8221;                                                                                                                                                                                                                                                                                                                             |
|            |               (iv) EP5 &#8220;Evaluation of Precision Performance of Clinical Chemistry Devices, February 1999,&#8221; and                                                                                                                                                                                                                                                                                                                                        |
|            |               (v) EP10 &#8220;Preliminary Evaluation of the Linearity of Quantitive Clinical Laboratory Methods, May 1998,&#8221;                                                                                                                                                                                                                                                                                                                                 |
|            |               (2) Centers for Disease Control's:                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (i) Low Titer Rubella Standard,                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1994-12-01 | The special controls for this device are:                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (1) National Committee for Clinical Laboratory Standards':                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (i) 1/LA6 &#8220;Detection and Quantitation of Rubella IgG Antibody: Evaluation and Performance Criteria for Multiple Component Test Products, Speciment Handling, and Use of the Test Products in the Clinical Laboratory, October 1997,&#8221;                                                                                                                                                                                                    |
|            |               (ii) 1/LA18 &#8220;Specifications for Immunological Testing for Infectious Diseases, December 1994,&#8221;                                                                                                                                                                                                                                                                                                                                          |
|            |               (iii) D13 &#8220;Agglutination Characteristics, Methodology, Limitations, and Clinical Validation, October 1993,&#8221;                                                                                                                                                                                                                                                                                                                             |
|            |               (iv) EP5 &#8220;Evaluation of Precision Performance of Clinical Chemistry Devices, February 1999,&#8221; and                                                                                                                                                                                                                                                                                                                                        |
|            |               (v) EP10 &#8220;Preliminary Evaluation of the Linearity of Quantitive Clinical Laboratory Methods, May 1998,&#8221;                                                                                                                                                                                                                                                                                                                                 |
|            |               (2) Centers for Disease Control's:                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (i) Low Titer Rubella Standard,                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1993-10-01 | The special controls for this device are:                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (1) National Committee for Clinical Laboratory Standards':                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (i) 1/LA6 &#8220;Detection and Quantitation of Rubella IgG Antibody: Evaluation and Performance Criteria for Multiple Component Test Products, Speciment Handling, and Use of the Test Products in the Clinical Laboratory, October 1997,&#8221;                                                                                                                                                                                                    |
|            |               (ii) 1/LA18 &#8220;Specifications for Immunological Testing for Infectious Diseases, December 1994,&#8221;                                                                                                                                                                                                                                                                                                                                          |
|            |               (iii) D13 &#8220;Agglutination Characteristics, Methodology, Limitations, and Clinical Validation, October 1993,&#8221;                                                                                                                                                                                                                                                                                                                             |
|            |               (iv) EP5 &#8220;Evaluation of Precision Performance of Clinical Chemistry Devices, February 1999,&#8221; and                                                                                                                                                                                                                                                                                                                                        |
|            |               (v) EP10 &#8220;Preliminary Evaluation of the Linearity of Quantitive Clinical Laboratory Methods, May 1998,&#8221;                                                                                                                                                                                                                                                                                                                                 |
|            |               (2) Centers for Disease Control's:                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (i) Low Titer Rubella Standard,                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1999-02-01 | The special controls for this device are:                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (1) National Committee for Clinical Laboratory Standards':                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (i) 1/LA6 &#8220;Detection and Quantitation of Rubella IgG Antibody: Evaluation and Performance Criteria for Multiple Component Test Products, Speciment Handling, and Use of the Test Products in the Clinical Laboratory, October 1997,&#8221;                                                                                                                                                                                                    |
|            |               (ii) 1/LA18 &#8220;Specifications for Immunological Testing for Infectious Diseases, December 1994,&#8221;                                                                                                                                                                                                                                                                                                                                          |
|            |               (iii) D13 &#8220;Agglutination Characteristics, Methodology, Limitations, and Clinical Validation, October 1993,&#8221;                                                                                                                                                                                                                                                                                                                             |
|            |               (iv) EP5 &#8220;Evaluation of Precision Performance of Clinical Chemistry Devices, February 1999,&#8221; and                                                                                                                                                                                                                                                                                                                                        |
|            |               (v) EP10 &#8220;Preliminary Evaluation of the Linearity of Quantitive Clinical Laboratory Methods, May 1998,&#8221;                                                                                                                                                                                                                                                                                                                                 |
|            |               (2) Centers for Disease Control's:                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (i) Low Titer Rubella Standard,                                                                                                                                                                                                                                                                                                                                                                                                                     |
| 1998-05-01 | The special controls for this device are:                                                                                                                                                                                                                                                                                                                                                                                                                         |
|            |               (1) National Committee for Clinical Laboratory Standards':                                                                                                                                                                                                                                                                                                                                                                                          |
|            |               (i) 1/LA6 &#8220;Detection and Quantitation of Rubella IgG Antibody: Evaluation and Performance Criteria for Multiple Component Test Products, Speciment Handling, and Use of the Test Products in the Clinical Laboratory, October 1997,&#8221;                                                                                                                                                                                                    |
|            |               (ii) 1/LA18 &#8220;Specifications for Immunological Testing for Infectious Diseases, December 1994,&#8221;                                                                                                                                                                                                                                                                                                                                          |
|            |               (iii) D13 &#8220;Agglutination Characteristics, Methodology, Limitations, and Clinical Validation, October 1993,&#8221;                                                                                                                                                                                                                                                                                                                             |
|            |               (iv) EP5 &#8220;Evaluation of Precision Performance of Clinical Chemistry Devices, February 1999,&#8221; and                                                                                                                                                                                                                                                                                                                                        |
|            |               (v) EP10 &#8220;Preliminary Evaluation of the Linearity of Quantitive Clinical Laboratory Methods, May 1998,&#8221;                                                                                                                                                                                                                                                                                                                                 |
|            |               (2) Centers for Disease Control's:                                                                                                                                                                                                                                                                                                                                                                                                                  |
|            |               (i) Low Titer Rubella Standard,                                                                                                                                                                                                                                                                                                                                                                                                                     |


